BMS-986504 demonstrates sturdy responses in MTAP-deleted NSCLC, together with EGFR and ALK-positive tumors

BMS-986504, a first-in-class methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) focusing on agent, confirmed promising antitumor exercise in closely pretreated sufferers with MTAP-deleted non-small cell lung most cancers (NSCLC), based on outcomes from the Section I CA240-0007 trial offered on the Worldwide Affiliation for the Research of Lung Most cancers 2025 World Convention on Lung Most cancers (WCLC).

MTAP, encoding the enzyme methylthioadenosine phosphorylase, is poor in lots of cancers. MTA is a byproduct of mobile metabolism that builds up in most cancers cells with a selected deletion: the MTAP gene.

When MTAP is deleted (MTAP-deleted cancers), MTA accumulates and binds to PRMT5, an enzyme that performs a task in cell regulation and survival. BMS-986504 is designed to selectively goal and inhibit PRMT5 when it is sure to MTA (PRMT5-MTA complicated), resulting in cell demise in MTAP-deleted most cancers cells.

The examine enrolled sufferers with superior stable tumors harboring homozygous MTAP deletions, a genetic alteration that happens in 10–15% of all cancers, and NSCLC represents as much as 27% of sufferers with MTAP-del.

Amongst clinically evaluable sufferers within the NSCLC cohort (n=35), BMS-986504 demonstrated a 29% general response charge (ORR) and a 80% illness management charge. Two further sufferers had unconfirmed responses and have been awaiting confirmatory scans. Responses included sufferers with EGFR and ALK alterations who had progressed on prior TKIs.

“BMS-986504 selectively targets the PRMT5-MTA complicated in MTAP-deleted cells whereas sparing regular tissue, offering a precision strategy for a difficult-to-treat affected person inhabitants,” stated Dr. Pasi Jänne of Dana-Farber Most cancers Institute, who offered the findings.

“These outcomes assist continued growth of this agent.”

Dr. Jänne reported some further key findings:

• Responses have been seen in 4/7 EGFR-positive, 2/4 ALK-positive, and 1/3 squamous sufferers.
• Median length of response: 10.5 months; time to response: 4.3 months.
• Median follow-up: 11.7 months (95% CI, 4.2–12.4).

Dr. Jänne stated that BMS-986504 was nicely tolerated, with most treatment-related hostile occasions (TRAEs) being grade 1 or 2; 14% of stable tumor sufferers skilled grade ≥3 TRAEs. Hematologic toxicity charges have been low and manageable with sufferers experiencing treatment-related anemia (8%), neutropenia (7%), and thrombocytopenia (7%).

The examine included stable tumor sufferers with nearly all of sufferers with NSCLC, mesothelioma, pancreatic ductal adenocarcinoma (PDAC), and cholangiocarcinoma. In accordance with Dr. Jänne, no new security alerts have been noticed throughout tumor sorts.

These outcomes assist additional investigation of BMS-986504 and there are two research for sufferers with superior NSCLC with MTAP-del:

• A Multicenter, Randomized, Open-label, Section II Research Evaluating the Security and Efficacy of BMS-986504 Monotherapy in Members With Superior or Metastatic Non-small Cell Lung Most cancers (NSCLC) With Homozygous MTAP Deletion After Development on Prior Therapies—NCT06855771
• A Randomized Section II/III Research of BMS-986504 in Mixture With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Most cancers Members With Homozygous MTAP Deletion—NCT07063745

Supplied by
Worldwide Affiliation for the Research of Lung Most cancers